Minerva Neurosciences | NERV - أصول متداولة





أصول متداولة تغيير تاريخ
Acadia Pharmaceuticals USD 1.27B 43.88M 2026-09
Adma Biologics USD 575.86M 47.66M 2026-09
ALKERMES USD 1.58B 57.83M 2026-09
Alterity Therapeutics Limited AUD 37.91M 15.92M 2025-12
AstraZeneca USD 31.45B 3.48B 2026-09
BioCryst Pharmaceuticals USD 531.15M 46.47M 2026-09
Bristol-Myers Squibb USD 29.77B 1.19B 2026-09
Cipla INR 250.61B 9.14B 2026-09
Clal Biotechnology ILS 14.69M 1.95M 2023-12
Compugen USD 129.41M 7.88M 2026-06
CSL USD 11.85B 1000K 2025-12
Eli Lilly USD 65.26B 591M 2026-09
GlaxoSmithKline GBP 17.9B 336M 2026-09
Grifols EUR 5.96B 316.31M 2025-12
Halozyme Therapeutics USD 1.85B 913.71M 2026-09
Ionis Pharmaceuticals USD 2.49B 446.73M 2026-06
J&J USD 56.35B 3.42B 2026-09
Merck USD 38.94B 2.26B 2026-09
Minerva Neurosciences USD 83.1M 70.08M 2025-12
Neurocrine Biosciences USD 2.01B 370.7M 2026-09
Novartis USD 28.75B 1.4B 2026-09
Novavax USD 707.96M 63.14M 2026-09
Pfizer USD 45.01B 3.65B 2026-09
Roche Holding CHF 35.44B 3.29B 2026-06
Sanofi EUR 33.21B 1.68B 2026-09
Takeda JPY 3T 153.11B 2026-09
Vanda Pharmaceuticals USD 347.26M 20.23M 2025-12